The FDA has granted Coya 302 a fast-track designation for ALS, according to a press release from Coya Therapeutics. “ALS is a ...
Acurastem has received $7.5 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance AS-241, its lead clinical candidate for amyotrophic lateral sclerosis (ALS) and ...
COYA 302, an injection therapy in development for the treatment of ALS, has been awarded fast track status by the U.S. Food and Drug Administration. The therapy aims to slow ALS progression by ...
With the help of artificial intelligence, a coalition of Bay Area institutions identified 18 FDA-approved drugs that could improve the lives of those suffering from amyotrophic lateral sclerosis, ...
May is National ALS Awareness Month, raising awareness about Amyotrophic Lateral Sclerosis (ALS), also known as “Lou Gehrig’s Disease.” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results